• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Afferi L, Spahn M, Hayoz S, Strebel R, Rothschild S, Seifert H, Özdemir B, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Schneider M, Musilova J, Petrausch U, Cathomas R. Surgical safety and quality of radical cystectomy and pelvic lymph node dissection after neoadjuvant Durvalumab and Cisplatin/Gemcitabine for muscle invasive bladder cancer: Results from the SAKK 06/17 phase II study. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00214-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
2
Hiltbrunner S, Britschgi C, Schuberth P, Bankel L, Nguyen-Kim T, Gulati P, Weder W, Opitz I, Lauk O, Caviezel C, Bachmann H, Tabor A, Schröder P, Knuth A, Münz C, Stahel R, Boyman O, Renner C, Petrausch U, Curioni-Fontecedro A. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol 2021;32:120-121. [DOI: 10.1016/j.annonc.2020.10.474] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Revised: 10/07/2020] [Accepted: 10/12/2020] [Indexed: 10/23/2022]  Open
3
Joerger M, Metaxas Y, Schmitt A, Koeberle D, Zaman K, Betticher D, Mach N, Renner C, Mark M, Petrausch U, Caspar C, Britschgi C, Taverna C, Zenger F, Mingrone W, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R. LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA). Ann Oncol 2020. [PMCID: PMC7506361 DOI: 10.1016/j.annonc.2020.08.2321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]  Open
4
Curioni A, Britschgi C, Hiltbrunner S, Bankel L, Gulati P, Weder W, Opitz I, Lauk O, Caviezel C, Knuth A, Münz C, Renner C, Stahel R, Petrausch U. A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.052] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
5
Mauti L, Klingbiel D, Schmid S, Bouchaab H, Bartnick T, Gautschi O, Rothschild S, Loeffler M, Froesch P, Petrausch U, Wolleb Schild S, Mingrone W, Pratsch Peter S, Savic Prince S, Pless M, von Moos R, Metaxas Y. Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: A Swiss registry. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx389] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
6
Abdel-Rahman O, Helbling D, Schmidt J, Petrausch U, Giryes A, Mehrabi A, Schöb O, Mannhart M, Oweira H. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol) 2017;29:218-230. [DOI: 10.1016/j.clon.2016.11.007] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Revised: 10/12/2016] [Accepted: 10/14/2016] [Indexed: 01/22/2023]
7
Stahel R, Weder W, Felley-Bosco E, Petrausch U, Curioni-Fontecedro A, Schmitt-Opitz I, Peters S. Searching for targets for the systemic therapy of mesothelioma. Ann Oncol 2015;26:1649-60. [DOI: 10.1093/annonc/mdv101] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Accepted: 02/12/2015] [Indexed: 12/19/2022]  Open
8
Petrausch U, Pestalozzi BC. Distinct clinical and prognostic features of invasive lobular breast cancer. Breast Dis 2012;30:39-44. [PMID: 19850994 DOI: 10.3233/bd-2009-0280] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
9
Petrausch U, Samaras P, Mischo A, Stenner F, Tinguely M, Schäfer N, Studer G, Renner C. [After care in Hodgkin lymphoma]. Praxis (Bern 1994) 2011;100:1515-1522. [PMID: 22161876 DOI: 10.1024/1661-8157/a000744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
10
Petrausch U, Samaras P, Haile S, Veit-Haibach P, Soyka J, Knuth A, Hany T, Mischo A, Renner C, Schäefer N. Risk-adapted FDG–PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010;21:1694-1698. [DOI: 10.1093/annonc/mdq015] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
11
Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka J, Knuth A, Hany T, Mischo A, Renner C, Schaefer N. Hodgkin’s lymphoma in remission after first-line therapy: which patients need FDG–PET/CT for follow-up? Ann Oncol 2010;21:1053-7. [DOI: 10.1093/annonc/mdp519] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
12
Petrausch U, Dernedde J, Coelho V, Panjideh H, Frey D, Fuchs H, Thiel E, Deckert PM. A33scFv Green fluorescent protein, a recombinant single-chain fusion protein for tumor targeting. Protein Eng Des Sel 2007;20:583-90. [DOI: 10.1093/protein/gzm043] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
13
Petrausch U, Martus P, Tönnies H, Bechrakis NE, Lenze D, Wansel S, Hummel M, Bornfeld N, Thiel E, Foerster MH, Keilholz U. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2007;22:997-1007. [PMID: 17384575 DOI: 10.1038/sj.eye.6702779] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA